应用液滴数字聚合酶链反应检测微小残留病：一项前瞻性多机构研究。
Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study.
机构信息
Department of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
出版信息
In Vivo. 2019 Nov-Dec;33(6):2273-2280. doi: 10.21873/invivo.11733.
BACKGROUND/AIM: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in chronic myeloid leukemia (CML) patients.
PATIENTS AND METHODS
Between May 2013 and November 2014, CML patients treated with nilotinib were enrolled in our study. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). We enrolled 15 patients from 7 Institutions. The treatment period and median follow-up period were 45 months and 47 months, respectively.
RESULTS
Patients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (p=0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR compared to those with a high level (p=0.032).
CONCLUSION
We found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response.
背景/目的：液滴数字聚合酶链反应（ddPCR）是一种测量核酸的精确方法。本前瞻性研究的目的是使用 ddPCR 检测慢性髓系白血病（CML）患者的微小残留病（MRD）。
患者与方法
2013 年 5 月至 2014 年 11 月，我们招募了接受尼罗替尼治疗的 CML 患者参与本研究。在首次完全分子反应（CMR）时使用 ddPCR 评估 BCR/ABL1 转录本水平。我们从 7 家机构招募了 15 名患者。治疗期和中位随访期分别为 45 个月和 47 个月。
结果
在随访期间，BCR/ABL1 转录本水平较高的患者更倾向于失去 CMR（p=0.095）。此外，与 BCR/ABL1 转录本水平较高的患者相比，BCR/ABL1 转录本水平较低的患者 CMR 持续时间更长（p=0.032）。
结论
我们发现 ddPCR 是一种检测 MRD 的敏感方法，MRD 可能会影响治疗反应的持续时间。
Zotero 插件